Business Wire

VA-REGULA

30.4.2024 09:01:34 CEST | Business Wire | Press release

Share
Uber Poland Boosts Safety and Speed of Driver Verification with Regula Solutions

Regula 70X9 document readers were shipped to three Uber Verification Centers in Warsaw, Krakow, and Poznan, which serve as dedicated hubs where drivers submit their driver’s licenses and identification documents for thorough verification. The shipment was fulfilled by Regula’s Polish distributor, Korporacja Wschód (KW), whose forensic experts also provided special training on how to use the new devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430896042/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Regula document readers power the driver verification process for Uber Poland (Photo: Business Wire)

The Regula 70X9 became the core element of Uber’s mission to enhance their safety protocols. It allows Uber employees to perform a comprehensive set of checks to authenticate an ID. The reader automatically identifies the document type; reads the data in all the document zones, including the visual zone, MRZ (machine-readable zone), RFID (radio frequency identification) chips, and barcodes; and cross-compares the obtained text and graphic data. Plus, the supplied document readers are equipped with Automatic Authenticity Control technology. At its core are automated checks that swiftly assess the integrity of the provided documents, detecting any signs of forgery or alteration. All of the above features, together with integrated light sources, significantly reduce the risk of mistakenly verifying forged documents.

The current workflow carried out by Uber’s employees includes:

Step 1. Comparison of the documents provided by the driver with the documents uploaded in the Uber application.

Step 2. Verification of Background Check Certificate.

Step 3. Authenticity verification of passport/ID and driver’s license with the Regula 70X9 reader.

Step 4. Taking a driver’s profile picture.

Step 5. Finalizing verification in the system: data input, document upload, and profile picture upload.

“The process of personally vetting drivers has been, and continues to be, a major logistical challenge, but we believe our efforts will help improve safety in transit. Thanks to the Regula device, the first stage went very smoothly for us. This process, although lengthy, is certainly effective,” says Marcin Konrad Moczyrog, Director and Global Manager at Uber Rides, Central & Eastern Europe.

Prior to the integration of the Regula 70X9, drivers’ documents were verified by Uber’s employees, either manually or via an application based on AI algorithms. The old method had two problems: it was time-consuming, and it did not guarantee protection against high-level forgeries of documents.

“Document fraud is constantly on the rise, and since counterfeited documents are becoming more sophisticated, manual checks are no longer enough. Some inherent document security features may be verified only with special equipment or software solutions. We are honored that our devices have become the cornerstone for a revamped verification process at Uber, and are pleased to see that it’s bearing fruit,” says Maris Kaminskis, Executive Director at Regula Europe.

For additional information, please visit the website.

About Uber

Uber is a technology application connecting passengers and drivers that has revolutionized the way people travel. Since its inception in 2009, Uber has experienced exponential growth, expanding its operations to numerous cities worldwide. Uber operates in more than 10,000 cities across more than 71 countries, making it one of the largest ride-hailing platforms globally.

In Poland, Uber is available in 25 locations.

About Korporacja Wschód

Founded in 1995, Korporacja Wschód is a family-run business that has continually evolved to meet the dynamic needs of high-technology sectors. As the distributor of Regula products in Poland since 1996, we have established ourselves as a vital link in delivering technological solutions to various enforcement and security agencies. Our expertise spans the development, integration, implementation, and distribution of advanced technology equipment, catering primarily to Border Guards, Police, Military, and a range of non-governmental enterprises and institutions. Our collaboration with Regula, a leader in forensic science technologies, underscores our commitment to offering cutting-edge solutions in document verification and security.

Learn more at https://korporacjawschod.pl.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430896042/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye